ABEONA THERAPEUTICS INC. Increase (Decrease) in Accounts Payable
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Accounts Payable of $7.67 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2019-03-18
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2018-12-31 was -$273.00K, a 176.69% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2018-09-30 was $4.55M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2018-06-30 was -$127.00K, a 105.90% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for the quarter ending 2018-03-31 was $3.52M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2018 was $7.67M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2017 was -$1.30M, a 146.15% decline from fiscal 2016.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2016 was $2.82M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts payable for fiscal 2015 was -$1.17M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $4.28M derived: sum of 2 quarters · filed 2019-03-18 | $4.15M derived: sum of 3 quarters · filed 2019-03-18 | $7.67M 10-K · filed 2019-03-18 |
| 2018-09-30 | $4.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $4.42M derived: sum of 2 quarters · filed 2018-11-09 | $7.94M 10-Q · filed 2018-11-09 | $8.29M derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $3.39M 10-Q · filed 2018-08-09 | $3.75M derived: sum of 3 quarters · filed 2019-03-18 | $2.17M derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-03-31 | $3.52M 10-Q · filed 2018-05-10 | $3.87M derived: sum of 2 quarters · filed 2019-03-18 | $2.29M derived: sum of 3 quarters · filed 2019-03-18 | $4.45M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$1.22M derived: sum of 2 quarters · filed 2019-03-18 | $930.00K derived: sum of 3 quarters · filed 2019-03-18 | -$1.30M 10-K · filed 2019-03-18 |
| 2017-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $574.00K derived: sum of 2 quarters · filed 2018-11-09 | -$1.66M 10-Q · filed 2018-11-09 | $124.00K derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$77.00K 10-Q · filed 2018-08-09 | $1.70M derived: sum of 3 quarters · filed 2019-03-18 | $1.51M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | -$2.23M 10-Q · filed 2018-05-10 | -$450.00K derived: sum of 2 quarters · filed 2019-03-18 | -$642.00K derived: sum of 3 quarters · filed 2019-03-18 | $421.00K derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $1.59M derived: sum of 2 quarters · filed 2019-03-18 | $2.65M derived: sum of 3 quarters · filed 2019-03-18 | $2.82M 10-K · filed 2019-03-18 |
| 2016-09-30 | -$192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $871.00K derived: sum of 2 quarters · filed 2017-11-14 | $1.04M 10-Q · filed 2017-11-14 | $945.00K derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $1.23M 10-Q · filed 2017-08-14 | $1.14M derived: sum of 3 quarters · filed 2017-08-14 | $787.00K derived: sum of 4 quarters · filed 2017-08-14 |
| 2016-03-31 | $167.00K 10-Q · filed 2017-05-15 | $74.00K derived: sum of 2 quarters · filed 2017-05-15 | -$276.00K derived: sum of 3 quarters · filed 2017-05-15 | $251.00K derived: sum of 4 quarters · filed 2017-05-15 |
| 2015-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$443.00K derived: sum of 2 quarters · filed 2017-03-30 | $84.00K derived: sum of 3 quarters · filed 2017-03-30 | -$1.17M 10-K · filed 2017-03-30 |
| 2015-09-30 | -$350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $177.00K derived: sum of 2 quarters · filed 2016-11-14 | -$1.08M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$731.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$1.26M 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |